3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Lung Neoplasms
9
Carcinoma, Non-Small-Cell Lung
7
Pleural Effusion, Malignant
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Thoracic Neoplasms
1
Small Cell Lung Carcinoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Limited Stage Small Cell Lung Cancer
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Fatigue
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Cachexia
1
Brain Neoplasms
1
Interventions
Etoposide
156
Carboplatin
146
Cisplatin
106
Topotecan
76
durvalumab
52
atezolizumab
51
Irinotecan
45
pembrolizumab
39
Paclitaxel
34
Nivolumab
33
Radiotherapy
31
PM 01183
25
Drug Therapy
24
anlotinib
23
Gemcitabine
21
apatinib
19
Ipilimumab
18
Docetaxel
17
Temozolomide
16
Platinum
16
Radiosurgery
15
Pemetrexed
14
toripalimab
13
tislelizumab
13
olaparib
13
Magnetic Resonance Spectroscopy
13
Bevacizumab
13
rovalpituzumab tesirine
11
amrubicin
11
Specimen Handling
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Small Cell Lung Carcinoma
×
Sodium Chloride
×
Thoracic
×
Clear all
NCT04624204
2026-05-26
MK 7339-013
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
672 enrolled